Ozuriftamab Biosimilar – Anti-ROR2 mAb – Research Grade

The Structure of Ozuriftamab Biosimilar – Anti-ROR2 mAb

Ozuriftamab Biosimilar, also known as Anti-ROR2 mAb, is a monoclonal antibody that is designed to target the receptor tyrosine kinase-like orphan receptor 2 (ROR2). This biosimilar is a highly specific and potent therapeutic agent that has been developed for the treatment of various diseases, including cancer. The structure of Ozuriftamab Biosimilar is composed of two heavy chains and two light chains, which are linked together by disulfide bonds. The heavy chains consist of four constant domains (CH1, CH2, CH3, and CH4) and one variable domain (VH), while the light chains consist of one constant domain (CL) and one variable domain (VL).

The variable domains of the heavy and light chains are responsible for the specificity of Ozuriftamab Biosimilar for its target, ROR2. These domains contain a unique sequence of amino acids that can bind specifically to the extracellular domain of ROR2. This binding initiates a cascade of events that ultimately leads to the inhibition of ROR2 signaling, making Ozuriftamab Biosimilar an effective therapeutic agent.

The Activity of Ozuriftamab Biosimilar – Anti-ROR2 mAb

The main activity of Ozuriftamab Biosimilar is its ability to bind to ROR2 and inhibit its signaling. ROR2 is a transmembrane protein that is involved in various signaling pathways, including the Wnt signaling pathway. This pathway plays a crucial role in cell proliferation, differentiation, and survival, and dysregulation of this pathway has been linked to the development and progression of many types of cancer.

By binding to ROR2, Ozuriftamab Biosimilar prevents the interaction of ROR2 with its ligands, which are essential for its activation. This results in the inhibition of downstream signaling events, leading to the suppression of cell growth and survival. Additionally, Ozuriftamab Biosimilar has been shown to induce antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC), which further contribute to its anti-tumor activity.

The Application of Ozuriftamab Biosimilar – Anti-ROR2 mAb

Ozuriftamab Biosimilar is primarily being developed for the treatment of cancer, specifically solid tumors that overexpress ROR2. These include breast cancer, lung cancer, ovarian cancer, and pancreatic cancer. The unique structure and activity of Ozuriftamab Biosimilar make it a promising therapeutic agent for these types of cancer, as it targets a key signaling pathway involved in their growth and progression.

In addition to its potential as a cancer treatment, Ozuriftamab Biosimilar also has applications in other diseases. ROR2 has been implicated in various autoimmune and inflammatory diseases, such as rheumatoid arthritis and psoriasis. By inhibiting ROR2 signaling, Ozuriftamab Biosimilar may have the potential to treat these conditions as well.

Furthermore, Ozuriftamab Biosimilar can also be used as a research tool to study ROR2 and its role in various diseases. Its high specificity and potency make it an ideal antibody for experiments and assays that require the inhibition of ROR2 signaling.

Conclusion

In summary, Ozuriftamab Biosimilar – Anti-ROR2 mAb is a highly specific and potent monoclonal antibody that targets the receptor tyrosine kinase-like orphan receptor 2 (ROR2). Its unique structure and activity make it a promising therapeutic agent for the treatment of various types of cancer and other diseases. As research and development continue, Ozuriftamab Biosimilar has the potential to become a valuable addition to the arsenal of treatments available for these diseases.